Infectious Diseases Department, University Hospital of Trieste, Trieste, Italy.
Department of Medicine, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Rev Med Virol. 2020 Jul;30(4):e2101. doi: 10.1002/rmv.2101. Epub 2020 Feb 26.
Dengue is an emerging mosquito-borne viral infection with increasing reports of outbreaks. The clinical picture ranges from a benign febrile illness through to severe and potentially fatal manifestations. No specific anti-viral treatment exists, and therapy only consists of supportive care. During the last three decades, several attempts to develop an effective vaccine have been made. The first dengue vaccine to obtain licensure was Dengvaxia, which was authorized in 2015 and is currently available in over 20 countries. Its use has been approved with strict limitations regarding age and serostatus of the recipients, highlighting the necessity for a more safe and efficacious vaccine. At present several vaccine, candidates are undergoing clinical and pre-clinical trials. The most advanced candidates are TDV and TDV 003/005, two live-attenuated vaccines, but another 15 vaccines are under development, introducing novel immunization strategies to the traditional dengue vaccine scenario. This work reviews the current research status on dengue vaccines.
登革热是一种新出现的蚊媒病毒感染，其暴发的报告越来越多。临床表现从良性发热性疾病到严重且可能致命的表现不等。目前尚无特效抗病毒治疗方法，治疗仅包括支持性护理。在过去的三十年中，人们已经进行了几次开发有效疫苗的尝试。第一种获得许可的登革热疫苗是 Dengvaxia，于 2015 年获得授权，目前在 20 多个国家使用。其使用受到严格限制，包括年龄和受种者的血清状态，这突出表明需要更安全有效的疫苗。目前，有几种候选疫苗正在进行临床和临床前试验。最先进的候选疫苗是 TDV 和 TDV 003/005，两种减毒活疫苗，但还有另外 15 种疫苗正在开发中，为传统的登革热疫苗方案引入了新的免疫策略。本文综述了登革热疫苗的最新研究进展。
